 |
Cell Metabolism |
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies |
 |
Lancet Oncology |
TOMAS: an open-label, phase 1b study from the Italian Sarcoma Group. |
 |
Jci |
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies |
 |
Cancer Research |
High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis |
 |
Nature Communications |
Article | OPEN | Published: 12 June 2018 Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies |
 |
Science Translational Medicine |
A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent |
 |
Lancet Oncology |
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis |
 |
Cancer Discovery |
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer |
 |
Nature |
The genomic landscape of response to EGFR blockade in colorectal cancer |
 |
Nat Med. |
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. |
